GSTM1 and myelodysplastic syndrome: Non‐transfusion‐dependent anaemia of patients with all subtypes of LR‐MDS should be considered for treatment only when symptomatic, which means that it could be difficult to point to a specific threshold of Hb, given the possible impact on the occurrence of symptoms of comorbidities, especially cardiac.